股本结构
单位：万股
| 公告日期 | 2025-11-12 | 2025-11-06 | 2025-11-06 | 2025-11-12 | 2025-08-13 | 2025-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 6896.42 | 6883.04 | 6500.27 | 6454.41 | 5990.81 | 5966.12 |
| 普通股本 | 6896.42 | 6883.04 | 6500.27 | 6454.41 | 5990.81 | 5966.12 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-10 | 2025-11-07 | 2025-10-31 | 2025-09-30 | 2025-06-30 | 2025-05-12 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-12 | 6896.42 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-11-06 | 6883.04 | 未披露 |
更多>>
Common Stock offered 3,827,751 shares by the company
|
2025-11-07 |
| 2025-11-06 | 6500.27 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-11-12 | 6454.41 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with private placement and at-the-market program
Exercise of stock options
|
2025-09-30 |
| 2025-08-13 | 5990.81 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Conversion of preferred stock
Stock-based compensation
|
2025-06-30 |
| 2025-05-15 | 5966.12 | 未披露 | 定期报告 | 2025-05-12 |
| 2025-05-15 | 4548.38 | 1.41 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement
Issuance of common stock in connection with at-the-market program
Stock-based compensation
Share repurchases for the payment of employee taxes
Exercise of stock options
|
2025-03-31 |
| 2025-03-31 | 4548.38 | 未披露 | 定期报告 | 2025-03-27 |
| 2025-04-02 | 4544.35 | 未披露 |
更多>>
Common stock offered 12,219,736 shares by the company
|
2025-03-24 |
| 2025-03-24 | 3204.73 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-03-31 | 3157.47 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition.
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock-based compensation
Share repurchases for the payment of employee taxes
|
2024-12-31 |
| 2024-11-12 | 3156.85 | 未披露 | 定期报告 | 2024-11-07 |
| 2024-11-12 | 2619.84 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with the at-the-market program
|
2024-09-30 |
| 2024-08-13 | 2619.84 | 未披露 | 定期报告 | 2024-08-09 |
| 2024-08-13 | 2597.90 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock–based compensation
|
2024-06-30 |
| 2024-05-10 | 2592.42 | 未披露 | 定期报告 | 2024-05-08 |
| 2024-04-29 | 2560.85 | 未披露 | 定期报告 | 2024-04-15 |
| 2024-05-10 | 2508.56 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock–based compensation
Share repurchases for the payment of employee taxes
|
2024-03-31 |
| 2024-03-08 | 2481.34 | 未披露 | 定期报告 | 2024-03-05 |
| 2024-01-10 | 2405.87 | 未披露 | 定期报告 | 2024-01-09 |
| 2024-03-08 | 2397.75 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock in connection with the at-the-market program and purchase agreement
Exercise of Series B warrants
Stock-based compensation
Exercise of stock options
|
2023-12-31 |
| 2023-11-13 | 2263.76 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-13 | 2261.01 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with the at-the-market program and purchase agreement
|
2023-09-30 |
| 2023-08-11 | 2100.80 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-08-11 | 2098.58 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Stock-based compensation
|
2023-06-30 |
| 2023-05-15 | 2095.22 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-05-15 | 2094.78 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of warrants
Stock–based compensation
|
2023-03-31 |
| 2023-03-30 | 2094.78 | 未披露 | 定期报告 | 2023-03-27 |
| 2023-03-30 | 2086.13 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with the at-the-market program
Exercise of Series B warrants
Stock-based compensation
Exercise of stock options
|
2022-12-31 |
| 2022-11-04 | 2080.70 | 未披露 | 定期报告 | 2022-11-02 |
| 2022-11-04 | 2080.15 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of Series B warrants
Stock–based compensation
Issuance of common stock in connection with the at-the-market program
|
2022-09-30 |
| 2022-08-12 | 2057.98 | 未披露 | 定期报告 | 2022-08-09 |
| 2022-08-12 | 2009.96 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the at-the-market program
Stock–based compensation
|
2022-06-30 |
| 2022-05-13 | 1936.44 | 未披露 | 定期报告 | 2022-05-11 |
| 2022-04-27 | 1923.73 | 未披露 | 定期报告 | 2022-04-18 |
| 2022-05-13 | 1921.37 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with the at-the-market program
Stock–based compensation
Exercise of stock options
|
2022-03-31 |
| 2022-03-24 | 1898.98 | 未披露 | 定期报告 | 2022-03-23 |
| 2022-03-24 | 1884.58 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants in connection with registered direct offering
Issuance of common stock in connection with the at-the-market program
Issuance of common stock in connection with settlement with investors
Exercise of Series B warrants
Share-based compensation
Exercise of stock options
|
2021-12-31 |
| 2021-11-12 | 1730.05 | 未披露 | 定期报告 | 2021-11-10 |
| 2021-11-12 | 1729.54 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with the at-the-market program
Share–based compensation
Exercise of options
|
2021-09-30 |
| 2021-08-12 | 1689.68 | 未披露 | 定期报告 | 2021-08-10 |
| 2021-08-12 | 1689.19 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock and warrants in connection with registered direct offering
Issuance of common stock in connection with the at-the-market program
Issuance of common stock in connection with settlement with investors
Share–based compensation
Exercise of Series B warrants
|
2021-06-30 |
| 2021-06-08 | 1564.09 | 未披露 |
更多>>
1.Securities offered by the company pursuant to this prospectus 3,076,923 Shares.
|
2021-06-08 |
| 2021-05-07 | 1256.40 | 未披露 | 定期报告 | 2021-05-05 |
| 2021-04-26 | 1174.92 | 未披露 | 定期报告 | 2021-04-15 |
| 2021-05-07 | 1092.99 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Share–based compensation
Exercise of stock options
|
2021-03-31 |
| 2021-03-11 | 1092.99 | 未披露 | 定期报告 | 2021-03-07 |
| 2021-03-11 | 1088.25 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock in exchange for in-process research and development
Conversion of convertible notes into common stock upon close of the merger
Issuance of common stock and warrants in connection with pre-merger financing
Issuance of common stock, warrants and options to former Rexahn stockholders and effect of asset acquisition
Exercise of stock options
|
2020-12-31 |
| 2020-11-06 | 709.19 | 未披露 |
更多>>
Immediately after the Merger, there were approximately 7,091,878 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), outstanding (not including 3,749,992 Converted Additional Shares (as defined in Item 8.01 of this report) being held in escrow). The former stockholders and option holders of Ocuphire (including the Investors, as defined in Item 8.01 of this report) owned, or held rights to acquire, in the aggregate approximately 86.6% of the fully-diluted Common Stock, which for these purposes is defined as the outstanding Common Stock, plus outstanding options of the Company, and not including any Converted Additional Shares (the “Fully-Diluted Common Stock”), with the Company’s stockholders immediately prior to the Merger owning approximately 13.4% of the Fully-Diluted Common Stock. Pursuant to the Merger Agreement, the number of shares of Common Stock issued to Ocuphire’s stockholders for each share of Ocuphire’s common stock outstanding immediately prior to the Merger was calculated using an exchange ratio (the “Exchange Ratio”) of approximately 1.0565 shares of Common Stock for each share of Ocuphire common stock.
|
2020-11-06 |
| 2020-10-29 | 448.32 | 未披露 |
更多>>
From July 1, 2020 to September 10, 2020
Stock issued from warrant exchanges
|
2020-09-10 |
| 2020-08-27 | 423.41 | 未披露 | 定期报告 | 2020-08-10 |
| 2019-05-10 | 401.91 | 未披露 |
更多>>
From January 1, 2019 to April 12, 2019
Issuance of common stock and units, net of issuance costs
Common stock issued from vested restricted stock units
As a result of the reverse stock split, each 12 shares of issued Common Stock were converted into one share of Common Stock. Shareholders will receive cash in lieu of any fraction of a share that they would otherwise be entitled to receive as a result of the reverse stock split. The reverse stock split reduced the number of shares of outstanding Common Stock from approximately 48.3 million to approximately 4.0 million.
|
2019-04-12 |
| 2019-03-07 | 4828.30 | 未披露 | 定期报告 | 2019-03-07 |
| 2019-02-14 | 4827.74 | 未披露 | 定期报告 | 2019-02-11 |
| 2019-03-07 | 3752.74 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock and units, net of issuance costs
Common stock issued in exchange for services
Common stock issued from vested restricted stock units
|
2018-12-31 |
| 2018-11-02 | 3752.12 | 未披露 | 定期报告 | 2018-11-02 |
| 2018-11-02 | 3175.19 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-07-23 | 3175.19 | 未披露 | 定期报告 | 2018-07-10 |
| 2018-05-04 | 3174.44 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-09 | 3174.44 | 未披露 | 定期报告 | 2018-03-09 |
| 2018-03-09 | 3172.51 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
|
2017-12-31 |
| 2017-11-03 | 2845.98 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-04 | 2845.98 | 未披露 | 定期报告 | 2017-08-04 |
| 2017-08-04 | 2845.23 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-06-23 | 2845.23 | 未披露 | 定期报告 | 2017-06-19 |
| 2017-04-13 | 2542.20 | 未披露 |
更多>>
On April 13, 2017,Rexahn Pharmaceuticals, Inc. announced that it will implement a 1-for-10 reverse stock split of outstanding shares of the Company’s common stock. The reverse stock split will be effective on May 5, 2017.
|
2017-05-05 |
| 2017-05-03 | 25422.00 | 未披露 | 定期报告 | 2017-05-03 |
| 2017-05-03 | 24498.75 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-02-24 | 23744.38 | 未披露 | 定期报告 | 2017-02-21 |
| 2017-02-24 | 23736.88 | 未披露 |
更多>>
From December 31, 2015 to September 30, 2016
Issuance of common stock and units
Common stock issued in exchange for services
|
2016-09-30 |
| 2016-08-05 | 21330.88 | 未披露 | 定期报告 | 2016-08-05 |
| 2016-08-05 | 21323.38 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-06 | 21317.38 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-14 | 21311.38 | 未披露 | 定期报告 | 2016-03-11 |
| 2016-03-14 | 19741.38 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
Retirement of treasury stock
|
2015-12-31 |
| 2015-11-02 | 18074.71 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-07 | 18069.98 | 未披露 | 定期报告 | 2015-08-07 |
| 2015-08-07 | 18062.48 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-08 | 17956.64 | 未披露 | 定期报告 | 2015-05-08 |
| 2015-05-08 | 17921.02 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-16 | 17921.02 | 未披露 | 定期报告 | 2015-03-16 |
| 2015-03-16 | 17836.65 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
|
2014-12-31 |
| 2014-11-12 | 17825.33 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-13 | 17825.33 | 未披露 | 定期报告 | 2014-08-13 |
| 2014-08-13 | 17815.33 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-14 | 17799.71 | 未披露 | 定期报告 | 2014-05-14 |
| 2014-05-14 | 17664.11 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-03-21 | 17653.35 | 未披露 | 定期报告 | 2014-03-21 |
| 2014-03-21 | 14671.78 | 未披露 |
更多>>
from December 31, 2012 to December 31, 2013
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
|
2013-12-31 |
| 2013-11-13 | 13444.29 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-08-12 | 13421.79 | 未披露 | 定期报告 | 2013-08-12 |
| 2013-08-12 | 11980.56 | 未披露 | 定期报告 | 2013-06-30 |
| 2013-05-09 | 11942.90 | 未披露 | 定期报告 | 2013-05-09 |
| 2013-04-22 | 11942.89 | 未披露 | 定期报告 | 2013-04-18 |
| 2013-05-09 | 11944.32 | 未披露 | 定期报告 | 2013-03-31 |
| 2013-03-22 | 11942.90 | 未披露 |
更多>>
from December 31, 2011 to December 31, 2012
Issuance of common stock and units
|
2012-12-31 |
| 2012-08-08 | 9534.57 | 未披露 | 定期报告 | 2012-08-08 |
| 2012-08-08 | 9535.99 | 未披露 | 定期报告 | 2012-06-30 |
| 2012-05-09 | 9534.57 | 未披露 | 定期报告 | 2012-05-09 |
| 2012-05-09 | 9535.99 | 未披露 | 定期报告 | 2012-03-31 |
| 2011-11-09 | 9534.57 | 未披露 | 定期报告 | 2011-11-09 |
| 2011-11-09 | 9526.57 | 未披露 | 定期报告 | 2011-09-30 |
| 2011-05-09 | 9523.77 | 未披露 | 定期报告 | 2011-03-31 |
| 2011-03-16 | 8677.94 | 未披露 | 定期报告 | 2011-03-16 |
| 2011-03-16 | 8416.08 | 未披露 |
更多>>
from dec 31 2009 to dec 31 2010
Issuance of common stock and units
Common stock issued in exchange for services
Stock warrants exercised
Stock options exercised
|
2010-12-31 |
| 2010-11-15 | 8378.72 | 未披露 | 定期报告 | 2010-11-12 |
| 2010-11-15 | 8338.72 | 未披露 | 定期报告 | 2010-09-30 |
| 2010-08-16 | 8318.72 | 未披露 | 定期报告 | 2010-08-16 |
| 2010-08-16 | 8278.72 | 未披露 | 定期报告 | 2010-06-30 |
| 2010-05-21 | 7517.28 | 未披露 | 定期报告 | 2010-05-21 |
| 2010-05-21 | 7346.95 | 未披露 | 定期报告 | 2010-03-31 |
| 2010-03-31 | 7192.45 | 未披露 |
更多>>
from December 31, 2008 to December 31, 2009
Issuance of common stock and units, net of issuance costs
Stock options exercised
|
2009-12-31 |
| 2009-03-16 | 5602.56 | 未披露 |
更多>>
from December 31, 2007 to December 31, 2008
Common shares issued
Exercise of stock options
|
2008-12-31 |
Common Stock offered 3,827,751 shares by the company
From June 30, 2025 to September 30, 2025
Issuance of common stock in connection with private placement and at-the-market program
Exercise of stock options
From March 31, 2025 to June 30, 2025
Conversion of preferred stock
Stock-based compensation
From December 31, 2024 to March 31, 2025
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement
Issuance of common stock in connection with at-the-market program
Stock-based compensation
Share repurchases for the payment of employee taxes
Exercise of stock options
Common stock offered 12,219,736 shares by the company
From December 31, 2023 to December 31, 2024
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition.
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock-based compensation
Share repurchases for the payment of employee taxes
From June 30, 2024 to September 30, 2024
Issuance of common stock in connection with the at-the-market program
From March 31, 2024 to June 30, 2024
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock–based compensation
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with the at-the-market program and purchase agreement
Stock–based compensation
Share repurchases for the payment of employee taxes
From December 31,2022 to December 31,2023
Issuance of common stock in connection with the at-the-market program and purchase agreement
Exercise of Series B warrants
Stock-based compensation
Exercise of stock options
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with the at-the-market program and purchase agreement
From March 31, 2023 to June 30, 2023
Stock-based compensation
From December 31, 2022 to March 31, 2023
Exercise of warrants
Stock–based compensation
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with the at-the-market program
Exercise of Series B warrants
Stock-based compensation
Exercise of stock options
From June 30, 2022 to September 30, 2022
Exercise of Series B warrants
Stock–based compensation
Issuance of common stock in connection with the at-the-market program
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the at-the-market program
Stock–based compensation
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with the at-the-market program
Stock–based compensation
Exercise of stock options
From December 31, 2020 to December 31, 2021
Issuance of common stock and warrants in connection with registered direct offering
Issuance of common stock in connection with the at-the-market program
Issuance of common stock in connection with settlement with investors
Exercise of Series B warrants
Share-based compensation
Exercise of stock options
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with the at-the-market program
Share–based compensation
Exercise of options
From March 31, 2021 to June 30, 2021
Issuance of common stock and warrants in connection with registered direct offering
Issuance of common stock in connection with the at-the-market program
Issuance of common stock in connection with settlement with investors
Share–based compensation
Exercise of Series B warrants
1.Securities offered by the company pursuant to this prospectus 3,076,923 Shares.
From December 31, 2020 to March 31, 2021
Share–based compensation
Exercise of stock options
From December 31, 2019 to December 31, 2020
Issuance of common stock in exchange for in-process research and development
Conversion of convertible notes into common stock upon close of the merger
Issuance of common stock and warrants in connection with pre-merger financing
Issuance of common stock, warrants and options to former Rexahn stockholders and effect of asset acquisition
Exercise of stock options
Immediately after the Merger, there were approximately 7,091,878 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), outstanding (not including 3,749,992 Converted Additional Shares (as defined in Item 8.01 of this report) being held in escrow). The former stockholders and option holders of Ocuphire (including the Investors, as defined in Item 8.01 of this report) owned, or held rights to acquire, in the aggregate approximately 86.6% of the fully-diluted Common Stock, which for these purposes is defined as the outstanding Common Stock, plus outstanding options of the Company, and not including any Converted Additional Shares (the “Fully-Diluted Common Stock”), with the Company’s stockholders immediately prior to the Merger owning approximately 13.4% of the Fully-Diluted Common Stock. Pursuant to the Merger Agreement, the number of shares of Common Stock issued to Ocuphire’s stockholders for each share of Ocuphire’s common stock outstanding immediately prior to the Merger was calculated using an exchange ratio (the “Exchange Ratio”) of approximately 1.0565 shares of Common Stock for each share of Ocuphire common stock.
From July 1, 2020 to September 10, 2020
Stock issued from warrant exchanges
From January 1, 2019 to April 12, 2019
Issuance of common stock and units, net of issuance costs
Common stock issued from vested restricted stock units
As a result of the reverse stock split, each 12 shares of issued Common Stock were converted into one share of Common Stock. Shareholders will receive cash in lieu of any fraction of a share that they would otherwise be entitled to receive as a result of the reverse stock split. The reverse stock split reduced the number of shares of outstanding Common Stock from approximately 48.3 million to approximately 4.0 million.
from December 31, 2017 to December 31, 2018
Issuance of common stock and units, net of issuance costs
Common stock issued in exchange for services
Common stock issued from vested restricted stock units
from December 31, 2016 to December 31, 2017
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
On April 13, 2017,Rexahn Pharmaceuticals, Inc. announced that it will implement a 1-for-10 reverse stock split of outstanding shares of the Company’s common stock. The reverse stock split will be effective on May 5, 2017.
From December 31, 2015 to September 30, 2016
Issuance of common stock and units
Common stock issued in exchange for services
From December 31, 2014 to December 31, 2015
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
Retirement of treasury stock
from December 31, 2013 to December 31, 2014
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
from December 31, 2012 to December 31, 2013
Issuance of common stock and units
Common stock issued in exchange for services
Stock options exercised
Stock warrants exercised
from December 31, 2011 to December 31, 2012
Issuance of common stock and units
from dec 31 2009 to dec 31 2010
Issuance of common stock and units
Common stock issued in exchange for services
Stock warrants exercised
Stock options exercised
from December 31, 2008 to December 31, 2009
Issuance of common stock and units, net of issuance costs
Stock options exercised
from December 31, 2007 to December 31, 2008
Common shares issued
Exercise of stock options